Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Accelrys to Host Introductory Webinar and Online Discussion

Abstract:
Accelrys NanoBiology Initiative to Guide Drug Delivery and Diagnostic
Nanodesign Solutions through Academic, Government, Industry Collaboration

Accelrys to Host Introductory Webinar and Online Discussion on July 13, 2006

San Diego, CA | Posted on June 27, 2006

Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific solutions, today announced that it will host a free hour-long web-based seminar introducing the Accelrys NanoBiology Initiative, an international collaborative framework drawing on academia, government and industry to address the critical challenges of nanotechnology-enabled pharmaceutical and diagnostic design.

Focused on bridging the gap between the life sciences and material science at the nanoscale, the NanoBiology Initiative offers members the opportunity to guide the development of core modeling and workflow technologies for speeding innovative products to market. Led by Accelrys NanoBiology Initiative Director, Dr. Deepak Singh, the webinar will provide current and prospective members with an overview of the Initiative as well as a forum for discussion, questions and answers.

Date and Times:
July 13, 2006
Broadcast 1: 14:00 (GMT)/10:00 am (EDT)
Broadcast 2: 10:00 am (PDT)/1:00 pm (EDT)

To register for the Accelrys NanoBiology Initiative Introductory Webinar,
visit: www.accelrys.com/info/initiatives/nanobio/july13_webinar_registration.php


Amid rising competition from generic drug manufacturers, costly drug failures, a stricter regulatory climate and increasing pressure from an aging population, nanotechnology offers the pharmaceutical and diagnostic industries new tools and materials for overcoming those obstacles and driving future growth. As nanotechnology plays an increasingly critical role, it is imperative that scientists and engineers are armed with the powerful modeling, simulation and analytical tools necessary to efficiently assess and develop these highly complex systems. The Accelrys NanoBiology Initiative offers members the opportunity to define and prioritize the most critical challenges in this nascent sector and directly influence the core software solutions.

"Nanomaterials are fundamentally changing the biotechnology landscape, and our goal is to create a new set of computer-based R&D tools capable of anticipating those new needs and adding value every step of the way," said Dr. Deepak Singh. "From multiscale modeling that enables seamless design from the molecular level through full device to workflow platforms that automate R&D best practices across a company, the resulting technologies will provide improved efficiencies, faster time to market, and better return on investment for targeted medicine."

The second of two advanced technology programs Accelrys is currently leading in the area of nanotechnology, the NanoBiology Initiative follows on the success of Accelrys' Nanotechnology Consortium. Established in 2004 to guide the development of technologies for the design and analysis of advanced materials, the Nanotechnology Consortium has led to the creation of a robust suite of multiscale tools for Computer Aided NanoDesign (CAN).

####

About Accelrys:
Accelrys, Inc. (ACCL) is a leading provider of software and service solutions for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. Its materials research and development team is based at its European Headquarters and Centre of Excellence in Cambridge,

For more information, please click here.

Media Contact:
Rosalind Jackson
Antenna Group (for Accelrys)
rosalind@antennagroup.com
(415) 977-1923

Nathan Tinker
Antenna Group (for Accelrys)
nathan@antennagroup.com
(203) 229-0358

Copyright © Accelrys

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project